Protective Effects of Danlou Tablet (丹蒌片) against Murine Myocardial Ischemia and Reperfusion Injury In Vivo

Qi, Junyuan; Wang, Lei; Gu, Dongsheng; Guo, Liheng; Zhu, Wei; Zhang, Minzhou

doi:10.1007/s11655-016-2448-7

Cited by 16 publications

(11 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The murine model of I/R has been described in detail in our previous studies. (9)(10)(11) Briefly, mice were anesthetized with sodium pentobarbital (60 mg/kg, intraperitoneal injection, i.p), intubated, and ventilated with room air at a rate of 110 strokes/min and with a tidal volume of 0.25 mL using a mouse ventilator (Inspira, Harvard Apparatus, Holliston, MS, USA). The chest was opened through a left thoracotomy under a dissecting microscope.…”

Section: Myocardial I/r Model and Phaseⅰ Protocol In Micementioning

confidence: 99%

Protective Mechanisms of Suxiao Jiuxin Pills (速效救心丸) on Myocardial Ischemia-Reperfusion Injury in vivo and in vitro

Tan¹,

Yu²,

Pan³

et al. 2020

Chin. J. Integr. Med.

Self Cite

View full text Add to dashboard Cite

Percutaneous coronary intervention (PCI) is a milestone in treating acute myocardial infarction (AMI). Early reperfusion can instantaneously open the occluded coronary artery, rescuing the ischemic myocardium. (1) However, myocardial ischemia and reperfusion (I/R) injury, which can trigger death of myocytes, seriously affects clinical effectiveness of PCI. An animal study showed that 50% of the infarct area were caused by myocardial I/R injury. (2) Many signaling molecules and mechanisms are postulated to modulate myocardial I/R injury, such as calcium overload, reactive oxygen species, energy metabolism dysfunction of myocardial fibers, cellular adhesion molecules, neutrophils, vascular endothelial cells, and apoptosis, etc. (1) Several agents, such as freeradical scavengers and inhibitors of the immune system, have been shown to protect heart from I/R injury. Although it has been actively studied for more than 35 years, myocardial I/R injury is still not yet treated effectively. The high mortality and non-availability of suitable drug treatments led to heightened interest in developing early stage therapies to prevent death of myocytes following myocardial I/R, and to improve the life span and quality in patients after AMI. (3) Suxiao Jiuxin Pill (速效救心丸, SXJ), which formula can be found in the latest 2015 Chinese Pharmacopoeia, is made up of 2 herbs, Rhizoma Chuanxiong and Borneolum. (4) SXJ contains 4 active ingredients: ferulic acid, menthol, borenol, and isoborneol; and is widely used for treating AMI and angina pectoris in China for more than 30 years. (5) Previous publications reported that SXJ could alleviate acute myocardial ischemia, prevent the formation of atherosclerosis (AS) and induce potent relaxation and inhibition on contraction in human artery.

show abstract

Section: Myocardial I/r Model and Phaseⅰ Protocol In Micementioning

confidence: 99%

Protective Mechanisms of Suxiao Jiuxin Pills (速效救心丸) on Myocardial Ischemia-Reperfusion Injury in vivo and in vitro

Tan¹,

Yu²,

Pan³

et al. 2020

Chin. J. Integr. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…The reduced frequency and duration of ventricular tachycardia might be related to lowering the degree of myocardial ischemia and increasing ion transport channel-related enzyme activities (Na + -K + ATPase and CaATPase) [15]. Similarly, our recent studies also suggested that administration of Danlou Tablet could alleviate the severity of risk-region myocardial ischemia and reperfusion arrhythmia in vivo [30]. Moreover, recent studies revealed that puerarin, the main component of Danlou Tablet by UPLC-MS/MS analysis (Figure 1), could significantly protect cardiomyocytes from anoxia/reoxygenation injury in vitro [31, 32].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Danlou Tablet in Patients with Non‐ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo‐Controlled, Randomized Trial

Wang

Zhao

Mao

et al. 2016

Evidence-Based Complementary and Alternative Medicine

Self Cite

View full text Add to dashboard Cite

This study seeks to investigate potential cardioprotection of Danlou Tablets in patients undergoing PCI with non-ST elevation acute coronary syndrome (NSTE-ACS). 219 patients with NSTE-ACS were randomised to Danlou Tablet pretreatment (n = 109) or placebo (n = 110). No patients received statins prior to PCI and all patients were given atorvastatin (10 mg/day) after procedure. The main endpoint was the composite incidence of major adverse cardiac events (MACEs) within 30 days after PCI. The proportion of patients with elevated levels of cTn I>5 × 99% of upper reference limit was significantly lower in the Danlou Tablet group at 8 h (22.0% versus 34.5%, p = 0.04) and 24 h (23.9% versus 38.2%, p = 0.02) after PCI. The 30-day MACEs occurred in 22.0% of the Danlou Tablet group and 33.6% in the placebo group (p = 0.06). The incidence of MACE at 90-day follow-up was significantly decreased in the Danlou Tablet group compared to the placebo group (23.9% versus 37.3%, p = 0.03). The difference between the groups at 90 days was the incidence of nonfatal myocardial infarction (22% versus 34.5%, p = 0.04). These findings might support that treatment with Danlou Tablet could reduce the incidence of periprocedural myocardial infarction in patients with ACS undergoing PCI.

show abstract

“…Danlou tablet can decreased the expressions of inflammation cytokines by down regulating NF-kB singling pathway and accelerated cholesterol effluent through activating PPARa/ ABCA1 signaling pathway; inhibit EGFR phosphorylation and lower the expression of TNF-a, IL-6 and MMP9, decrease the expression levels of ox-LDL and MDA, and increase the expression of SOD. [28][29][30][31] Yixinshu capsule can attenuate ET-1 induced contraction dysfunction and BNP elevation, attenuate myocardial ischemia/reperfusion injury. [32][33][34][35][36] Xuezhikang capsule is extracts of red yeast, it contains natural statins.…”

Section: Pharmacological Effects and Possible Mechanisms Of Tradition...mentioning

confidence: 99%

Traditional Chinese medicine for acute coronary syndrome

Liao

Li²,

Hua³

et al. 2021

Medicine

View full text Add to dashboard Cite

Background:Modern clinical trials and experimental researches of traditional Chinese medicine (TCM) have been conducted for decades and provided support for the prevention and treatment of acute coronary syndrome (ACS). However the level of evidence and the proper application of TCM were still barely satisfactory.Methods:In this study, we divided ACS into 3 different stages, including unstable angina, acute myocardial infarction, and post myocardial infarction. Then we systematically reviewed and meta-analyzed the existing randomized controlled trials on both clinical manifestations and objective indicators, in these 3 aspects.Results:The results indicate that TCM can both improve the clinical manifestations and ameliorate the objective parameters in different courses of ACS, including C-reactive protein in unstable angina, left ventricular ejection fraction in acute myocardial infarction and post myocardial infarction. And the incidence of short-term cardiovascular events are lower in TCM intervention group. Some of the improvements lead to potential long-term benefits.Conclusion:TCM treatment is beneficial to different courses of ACS. To acquire more solid and comprehensive evidence of TCM in treating ACS, more rigorously designed randomized controlled trials with longer follow-up duration are warranted.

show abstract

Protective Effects of Danlou Tablet (丹蒌片) against Murine Myocardial Ischemia and Reperfusion Injury In Vivo

Abstract: Our research concluded that DLT was effective in reducing I/R injury in mice, and provided experimental supports for the clinical use of DLT.

Cited by 16 publications

References 19 publications

Protective Mechanisms of Suxiao Jiuxin Pills (速效救心丸) on Myocardial Ischemia-Reperfusion Injury in vivo and in vitro

Protective Mechanisms of Suxiao Jiuxin Pills (速效救心丸) on Myocardial Ischemia-Reperfusion Injury in vivo and in vitro

Efficacy of Danlou Tablet in Patients with Non‐ST Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from a Multicentre, Placebo‐Controlled, Randomized Trial

Traditional Chinese medicine for acute coronary syndrome

Contact Info

Product

Resources

About